We generated a tetravalent dual specific fusion protein composed of the active moiety of Etanercept, TNFRII, and the scFv L19, a human scFv to ED-B which is currently used extensively in preclinical studies as well clinical trials to target B-FN in different kind of cancers [13,14]. The gene discussed is FN1; the disease is cancer.